(News Bulletin 247) – Transgene announced on Wednesday that it has initiated the phase I trial evaluating its oncolytic virus in non-small cell lung cancer (NSCLC) with the treatment of a first patient.
The biotech company expects the study to enroll up to 36 patients with advanced NSCLC, who have relapsed after standard treatments, including immune checkpoint inhibitors.
The end of the trial is scheduled for the second half of 2024.
TG6050, an oncolytic virus from the Transgene platform, is armed with an antibody associated with a cytokine known to trigger a powerful antitumor immune response.
The objective is to locally express immunotherapies in the tumor microenvironment and thus to induce a stronger and more effective antitumor response.
The virus will be administered intravenously because patients with advanced NSCLC have disseminated disease with numerous metastases often invisible by medical imaging.
Listed on the Paris Stock Exchange, Transgene shares rose 3.4% on Wednesday following this announcement.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
